Pharsight

Prevymis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(7 months from now)

USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Feb, 2033

(9 years from now)

Prevymis is owned by Merck Sharp Dohme.

Prevymis contains Letermovir.

Prevymis has a total of 3 drug patents out of which 0 drug patents have expired.

Prevymis was authorised for market use on 08 November, 2017.

Prevymis is available in solution;intravenous dosage forms.

The generics of Prevymis are possible to be released after 28 February, 2033.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 5, 2030
New Indication (I) Jun 5, 2026

Drugs and Companies using LETERMOVIR ingredient

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PREVYMIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic